Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anybody here have access to Street Sweeper? Can u post related content? TIA!
I agree, I think this baby will shoot up like a rocket, soon, maybe next week. I've been working this stock since it was $0.80 back 4 to 5 years ago, it has been a superb success story. I just hate that I didn't had more $ available for it. Assuming that all numbers come out positive next week, or whenever they do their announcement, I think it will go way past the $50 mark this time.
Questcor announces preliminary Q4 operating metrics
In preparation for meetings starting Monday, January 9 with investors and an investor presentation scheduled for 10:00 a.m. Thursday, January 12 at the J. P. Morgan Healthcare Conference, Questcor Pharmaceuticals announced the following preliminary operating metrics for the fourth quarter 2011: Approximately 935-950 paid H.P. Acthar Gel prescriptions for the treatment of multiple sclerosis exacerbations during the quarter, up approximately 165% from the year ago quarter ended December 31, 2010; Approximately 140-150 paid Acthar prescriptions for the treatment of nephrotic syndrome during the quarter, up approximately 145% sequentially from the third quarter of 2011; Approximately 120-125 pai d Acthar prescriptions for the treatment of infantile spasms during the quarter, representing a new high for any quarter since Questcor formed its reimbursement support center and began tracking Acthar prescriptions in August 2007; 3,360 shipped vials of Acthar, up 100% from the quarter ended December 31, 2010. :theflyonthewall
Strong end of the year finish for QCOR
http://finance.yahoo.com/news/Questcor-Pharmaceuticals-prnews-2072944618.html?x=0
Yeah, QCOR is one of my favorites. I think once the company confirms strong numbers next week, we should be off to the races. They certainly seem to be getting more coverage from analysts lately
Sounds.good, been playing this baby since 14 bucks last year. Should be exciting next week 11 percent short interest or 6 days to.cover
I think it runs up next week. The recent weakness, imo, is from tax selling and bigger guys driving the price lower so they can get in before the next big run. $heff knows about QCOR. This was one of his picks from long time ago.
Hey buddy, thoughts on next week? grabbed some calls today.. I'd run this by sheff but i'm a freeloader here and can't post on his forum. thanks in advance.
Questcor management to meet with Jefferies
Meeting to be held in San Francisco on January 11 hosted by Jefferies. :theflyonthewall
Also from flyonthewall
Questcor weakness a buying opportunity, says Oppenheimer
Oppenheimer believes Questcor's script update today suggests as much as $6M-$9M upside to its Acthar revenue estimate for Q4. The firm recommends adding to positions amid today's weakness and keeps an Outperform rating on the stock. :theflyonthewall
Also from flyonethewall today:
From flyonthewall 38 minutes ago Questcor estimates raised on Acthar prescription trends at WJB Capital
WJB Capital raised its Acthar Q4 estimate to $71M from $67M, ahead of the consensus forecast of $66M, based on Acthar trends through November. WJB found today's update from Questcor as encouraging and maintains a Buy rating on the stock with a $50 price target. :theflyonthewall.com
News Breaks
December 12, 2011
13:10 EDT QCOR theflyonthewall.com: Questcor sinks after reporting Acthar prescriptions
Questcor (QCOR) is retreating after the company announced that there were 615-625 paid prescriptions of its main Acthar Gel for the treatment of multiple sclerosis from October 1 to November 30, down from 886 during its third quarter ended September 25. Prescriptions for Acthar for the treatment of nephrotic syndrome came in between 83-87 from October 1 to November 30, up from 60 in Q3. Finally, there were 88-92 new Acthar prescriptions for the treatment of infantile spasms, down from 112 in Q3. In a note to investors, Oppenheimer said Questcor's update is "largely positive." Questcor's Q4 revenue should exceed Oppenheimer's estimate of $66.6M by as much a $6M-$90m, added the firm. While Oppenheimer understands why people are concerned about the decline in MS prescriptions, it notes that prescriptions typically accelerate towards the end of each quarter, and it recommends buying the stock on today’s weakness. In mid-afternoon trading, Questcor fell $2.45, or 5.37%, to $43.14. :theflyonthewall.com
Sold 100 shares
@ $44.25 and bought at $1.25...
Shorted @ $45.86 and coverd at $42.68
1000 shares.....
Ron, Thanks.
But still if thats the case why no single institution invested in this for the last 8 Months.
also insiders sold all of their shares.
Reference to Lupus, we have seen Benlysta from HGSI/ Glaxo.
HGSI's highs reached upto 35$, and teh current price is $7...
Qcor Lupus i guess will take atleast 3 to 4 yrs from now.
Also the Europe is a major player, in terms of trading going forward for the next few months.
QCOR already spiked 300%.......
Wouldn't surprise me if this doubled next year.
I think it's still low.
The growth going forward for QCOR is ridiculous. They have only scratched the surface. Watch sales explode as they enter the Lupus market and when they announce they are going for the diabetes market, you will see a parabolic move. I urge you to listen to the last earnings conference call. It's an eye opener. Analysts are upgrading this stock left and right.
Ron, What is your opinion/View on Qcor.
I shorted it @45.86....
Do you really think it goes above $50, with the current market conditions.
I always see analysts give unrealistic price targets.
Also insiders sold majority of their holdings.
Since Apr 2011 haven't seen any institutional 13 D filings.
kind regards..
Great article . Great sales to come this q hopefully
$11 is a great entry point.
Sounds good I wish I got in at 4 dollars two years back . But in at 11.00 is not to bad especially if it gets to 75 . Have a good weekend
Thanks for the updates
What price do you think Qcor
Can get to in the 12 months
I am a investor from Dublin Ireland
Questcor initiated with an Outperform at Leerink :theflyonthewall
Questcor price target raised to $53 from $45 at Oppenheimer
Oppenheimer raised its price target for Questcor after its survey indicated that company's opportunity in multiple sclerosis for Acthar may be larger than previously expected. Opco said it would be a buyer of the stock ahead of the next Acthar script update which it believes could occur on December 12. :theflyonthewall
Don M. Bailey, CEO of Questcor Pharmaceuticals, named as one of top CEOs on Equities.com: http://editorial.equities.com/stocks/top-four-nice-ceos-of-2011/
Questcor initiated with a Buy at Ladenburg
Target $51. :theflyonthewall.com
Helps to be able to recognize them AS winners before others ?
To think this was .20 as QSC at one time
man oh man
hold your winners
lol
MK
How high can this go?
Jazz also went from $8 to 49$ & now it is at $36 change.....
There are 24 form (4)'s submitted on SEC, all insiders sold transactions pretty much everything in the range between 41$ and 43$
Insiders sold lot of shares, if pps reaching $50 or higher why would they sell their shares?
Now a days these analysts giving price targets which are ridiculous...
Nice SeekingAlpha article on QCOR
http://seekingalpha.com/article/310187-questor-pharmaceuticals-even-in-a-bad-market-fantastic-growth-looks-attractive
QCOR on Jim Cramer tonight
http://video.cnbc.com/gallery/?video=3000057860
Price target too low, imo.
Its only a (good) week away to reach.
Can't wait for the next schedule.
Also "TheStreet" and "Jaywalk Consensus" have it as a buy for what it's worth.
Questcor price target raised to $50 from $44 at Jefferies
Jefferies raised its price target for Questcor citing expectations for sustained Acthar sales growth in nephrotic syndrome. The firm keeps a Buy rating on the stock. :theflyonthewall
I do not really know what all of that means in the PR, but do know it probably means more sales and that is good stuff.
Most recent quarters earnings
http://finance.yahoo.com/news/Questcor-Reports-Third-prnews-3231279170.html?x=0&.v=1
I bought shares of qcor at $25 and am so happy in the results. I have been a pink sheet troll for many years and it is refreshing to have shares in a real company, with a real product with real results.
QCOR just keeps going and going. They are presenting at a conference so that may be why we are seeing this move up. Don't forget that next earnings release should be another blockbuster.
Still holding here.
# of prescriptions is still relatively low to the number of patients who could take it, imo.
Wow - cant believe I had 10,000 shares of this at $3 a few years back. I sold most of them for $8 - $12 per share and thought I made a nice profit. But now $40 -- should've been more patient.
Looks like you made a nice call in July. Nice after hours trading.
Followers
|
24
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
407
|
Created
|
04/30/09
|
Type
|
Free
|
Moderators |
At Questcor, we are a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Our efforts are currently focused on the fields of neurology and nephrology, areas of medicine which have significant unmet medical needs.
Our highly experienced Sales and Marketing teams are presently focused on increasing the usage of our primary marketed product, Acthar, among specialists who treat patients with multiple sclerosis, infantile spasms and nephrotic syndrome. In addition, our Medical Affairs personnel are working with leading researchers to explore promising additional uses for this important product in a variety of other conditions.
How we implement our business strategy:
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |